Company: NCEL
Filing Date: 2025-03-03
Form Type: F-4/A
Source: 0001213900-25-018981
Chunk: 332

Company: NewcelX Ltd.
Filing Date: 2025-03-03
Form: F-4/A
Chunk 332
---
 Zwyer, Director Alexander Zwyerhas served as NLS’s Chief Executive Officer and as a Director since NLS’s incorporation in August 2015. Mr. Zwyer has over 25 years of international business experience. In 2007, prior to, and until founding NLS in 2015, Mr. Zwyer founded a start -upin the high -endluxury food sector and served as its chief executive officer until 2015 when he successfully sold the company. From 1991 and until 2007, Mr. Zwyer served in various positions with Viforpharma AG (SWX: VIFN) (then known as Vifor (International) Inc.), most notably serving as Executive Vice President (chief operating officer), leading the company’s global regulatory affairs, medical affairs, sales and marketing as well as business development teams. Mr. Zwyer speaks seven languages fluently. Mr. Zwyer holds a B.B.A. in business administration from Oekral, Zurich, Switzerland and an executive M.B.A. from GSBA/Lorange Institute of Business, Zurich, Switzerland and an M.B.A. from University at Albany SUNY. Tammy Galili, Director Tammy Galili has served as a director at Kadimastem since July 2021. She has three decades of experience in various management positions in the pharmaceutical space. She served as the CEO of Ilex Medical Ltd. from January 2016 and until October 2024, and previously served as the company’s Deputy CEO from January 2014 until January 2014, and Vice President of Sales and Marketing from January 2010 until December 2013. Ms. Galili has an MBA in Healthcare Innovation from Reichman University in Herzliya and a BA in Philosophy and History of the Middle East in Modern Times from the Tel Aviv University. Director Independence Mr.Olivier Samuel, Mr.Eran Lohan and Ms. Liora Oren are the independent directors of Kadimastem. Kadimastem’s board of directors has determined that all of its current independent directors are independent, as determined in accordance with the rules of The Nasdaq Stock Market. Mr.Olivier Samuel, Mr.Eran Lohan and Ms. Liora Oren as members of each of the Audit, Compensation, Nomination and Governance Committees for a term lasting until the next annual ordinary shareholders’ meeting. The Kadimastem board of directors has also determined that each current